Mitogen Activated Protein Kinase Kinase Kinase 3 (MAP3K3/MEKK3) Overexpression is an Early Event in Esophageal Tumorigenesis and is a Predictor of Poor Disease Prognosis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Jan 4

PMID 24383423

Citations 15

Authors

Raghibul Hasan

Rinu Sharma

Anoop Saraya

Tushar K Chattopadhyay

Siddartha DattaGupta

Paul G Walfish

Shyam S Chauhan

Ranju Ralhan

Affiliations

Soon will be listed here.

Abstract

Background: Mitogen-activated protein kinase kinase kinase3 (MAP3K3/MEKK3) was identified to be differentially expressed in esophageal squamous cell carcinoma (ESCC) using cDNA microarrays by our laboratory. Here in we determined the clinical significance of MEKK3 in ESCC.

Methods: Immunohistochemical analysis of MEKK3 expression was carried out in archived tissue sections from 93 ESCCs, 47 histologically normal and 61 dysplastic esophageal tissues and correlated with clinicopathological parameters and disease prognosis over up to 7.5 years for ESCC patients.

Results: MEKK3 expression was significantly increased in esophageal dysplasia and ESCC in comparison with normal mucosa (ptrend < 0.001). Kaplan Meier survival analysis showed significantly reduced median disease free survival median DFS = 10 months in patients with MEKK3 positive ESCCs compared to patients with no immunopositivity (median DFS = 19 months, p = 0.04). ESCC patients with MEKK3 positive and lymph node positive tumors had median DFS = 9 months, as compared to median DFS = 21 months in patients who did not show the alterations (p = 0.01). In multivariate Cox regression analysis, combination of MEKK3 overexpression and node positivity [p = 0.015, hazard ratio (HR) = 2.082, 95% CI = 1.154 - 3.756] emerged as important predictor of reduced disease free survival and poor prognosticator for ESCC patients.

Conclusions: Alterations in MEKK3 expression occur in early stages of development of ESCC and are sustained during disease progression; MEKK3 in combination with lymph node positivity has the potential to serve as adverse prognosticator in ESCC.

Citing Articles

Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.

Park S, Ryu W, Kim T, Hwang Y, Han H, Lee J Exp Mol Med. 2024; 56(4):987-1000.

PMID: 38622197 PMC: 11059244. DOI: 10.1038/s12276-024-01210-5.

Prediction of recurrence free survival for esophageal cancer patients using a protein signature based risk model.

Hasan R, Srivastava G, Alyass A, Sharma R, Saraya A, Chattopadhyay T Oncotarget. 2022; 13:1020-1032.

PMID: 36128326 PMC: 9477219. DOI: 10.18632/oncotarget.10656.

Characterization and clustering of kinase isoform expression in metastatic melanoma.

Holland D, Gotea V, Fedkenheuer K, Jaiswal S, Baugher C, Tan H PLoS Comput Biol. 2022; 18(5):e1010065.

PMID: 35560144 PMC: 9132324. DOI: 10.1371/journal.pcbi.1010065.

Clinical Significance and Regulation of ERK5 Expression and Function in Cancer.

Monti M, Celli J, Missale F, Cersosimo F, Russo M, Belloni E Cancers (Basel). 2022; 14(2).

PMID: 35053510 PMC: 8773716. DOI: 10.3390/cancers14020348.

Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer.

Slater E, Wilke L, Bohm L, Strauch K, Lutz M, Gercke N J Pers Med. 2021; 11(7).

PMID: 34357098 PMC: 8305658. DOI: 10.3390/jpm11070631.

References

Greenwald B, Dumot J . Cryotherapy for Barrett's esophagus and esophageal cancer. Curr Opin Gastroenterol. 2011; 27(4):363-7. DOI: 10.1097/MOG.0b013e328347bae8. View

Wang J, Canto M . Predicting Neoplastic Progression in Barrett's Esophagus. Ann Gastroentol Hepatol. 2011; 1(1):1-10. PMC: 3087308. View

Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay T, Ralhan R . Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers. 2009; 23(4):231-7. DOI: 10.1177/172460080802300406. View

Wheeler J, Reed C . Epidemiology of esophageal cancer. Surg Clin North Am. 2012; 92(5):1077-87. DOI: 10.1016/j.suc.2012.07.008. View

Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K . Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial. Radiat Oncol. 2012; 7:142. PMC: 3494533. DOI: 10.1186/1748-717X-7-142. View

Gajalakshmi V, Swaminathan R, Shanta V . An Independent Survey to Assess Completeness of Registration: Population Based Cancer Registry, Chennai, India. Asian Pac J Cancer Prev. 2003; 2(3):179-183. View

Ralhan R, Desouza L, Matta A, Tripathi S, Ghanny S, Dattagupta S . iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2008; 8(1):300-9. DOI: 10.1021/pr800501j. View

Low D . Update on staging and surgical treatment options for esophageal cancer. J Gastrointest Surg. 2011; 15(5):719-29. DOI: 10.1007/s11605-011-1515-9. View

Kumar A, Chatopadhyay T, Raziuddin M, Ralhan R . Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer. 2006; 120(2):230-42. DOI: 10.1002/ijc.22246. View

10.

Bray F, Ren J, Masuyer E, Ferlay J . Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2012; 132(5):1133-45. DOI: 10.1002/ijc.27711. View

11.

Kaifi J, Gusani N, Jiang Y, Mackley H, Dye C, Mathew A . Multidisciplinary management of early and locally advanced esophageal cancer. J Clin Gastroenterol. 2011; 45(5):391-9. DOI: 10.1097/MCG.0b013e3182049949. View

12.

Omloo J, van Heijl M, Hoekstra O, van Berge Henegouwen M, van Lanschot J, Sloof G . FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011; 18(12):3338-52. PMC: 3192273. DOI: 10.1245/s10434-011-1732-1. View

13.

Ryan A, Duong M, Healy L, Ryan S, Parekh N, Reynolds J . Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol. 2011; 35(4):309-19. DOI: 10.1016/j.canep.2011.03.001. View

14.

Kausar T, Sharma R, Hasan M, Tripathi S, Saraya A, Chattopadhyay T . Clinical significance of GPR56, transglutaminase 2, and NF-κB in esophageal squamous cell carcinoma. Cancer Invest. 2010; 29(1):42-8. DOI: 10.3109/07357907.2010.512597. View

15.

Deng Y, Yang J, McCarty M, Su B . MEKK3 is required for endothelium function but is not essential for tumor growth and angiogenesis. Am J Physiol Cell Physiol. 2007; 293(4):C1404-11. DOI: 10.1152/ajpcell.00058.2007. View

16.

Hong J, Resnick M, Behar J, Wands J, DeLellis R, Cao W . Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells. Am J Physiol Cell Physiol. 2011; 301(2):C413-20. PMC: 3274187. DOI: 10.1152/ajpcell.00027.2011. View

17.

Lee J, Yang S, Yang P, Shun C, Wu M, Hsu C . Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol. 2011; 18(7):2066-73. DOI: 10.1245/s10434-011-1559-9. View

18.

Worni M, Martin J, Gloor B, Pietrobon R, DAmico T, Akushevich I . Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg. 2012; 215(5):643-51. PMC: 3479433. DOI: 10.1016/j.jamcollsurg.2012.07.006. View

19.

Samanta A, Huang H, Le X, Mao W, Lu K, Bast Jr R . MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 2009; 115(17):3897-908. PMC: 3061353. DOI: 10.1002/cncr.24445. View

20.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View